Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma

Pancreas

Volumn 42, Issue 4, 2013, Pages 663-669

  Mahawithitwong, Prawej ^a   Ohuchida, Kenoki ^a   Ikenaga, Naoki ^a   Fujita, Hayato ^a   Zhao, Ming ^a   Kozono, Shingo ^a   Shindo, Koji ^b   Ohtsuka, Takao ^a   Mizumoto, Kazuhiro ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Kindlin 2; pancreatic ductal adenocarcinoma; paraffin embedded tissue samples; prognostic factor; reverse transcription polymerase chain reaction; stromal cell

Indexed keywords

KINDLIN 2 PROTEIN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENERAL PATHOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876852414     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318279bd66     Document Type: Article

References (54)

1. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008; 10(1): 58-62.
2. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002; 236(3): 355-366; discussion 366-358.
3. Siegel R,Ward E, Brawley O, et al. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4): 212-236.
4. Nio Y, Dong M, Iguchi C, et al. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol. 2001; 76(3): 188-196.
5. Magistrelli P, Coppola R, Tonini G, et al. Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem. 2006; 97(1): 98-108.
6. Song MM, Nio Y, Sato Y, et al. Clinicopathological significance of Ki-ras point mutation and p21 expression in benign and malignant exocrine tumors of the human pancreas. Int J Pancreatol. 1996; 20(2): 85-93.
7. Dabritz J, Preston R, Hanfler J, et al. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: Correlation with clinical features and carbohydrate antigen 19-9. Pancreas. 2009; 38(5): 534-541.
8. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002; 20(23): 4531-4542.
9. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001; 7(12): 4115-4121.
10. Wagner M, Kleeff J, Lopez ME, et al. Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer. 1998; 78(2): 255-260.
11. Coppola D, Lu L, Fruehauf JP, et al. Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. Am J Clin Pathol. 1998; 110(1): 16-23.
12. Friess H, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 1993; 105(6): 1846-1856.
13. Tonini G, Pantano F, Vincenzi B, et al. Molecular prognostic factors in patients with pancreatic cancer. Expert Opin Ther Targets. 2007; 11(12): 1553-1569.
14. Smith RA, Tang J, Tudur-Smith C, et al. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer. 2011; 104(9): 1440-1451.
15. Singh P, Srinivasan R, Wig JD. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas. 2011; 40(5): 644-652.
16. Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: A systematic review. Eur J Cancer. 2005; 41(15): 2213-2236.
17. Wick M, Burger C, Brusselbach S, et al. Identification of serum-inducible genes: Different patterns of gene regulation during G0-9S and G1-9S progression. J Cell Sci. 1994; 107(Pt 1): 227-239.
18. Kloeker S, Major MB, Calderwood DA, et al. The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. J Biol Chem. 2004; 279(8): 6824-6833.
19. Shi X, Ma YQ, Tu Y, et al. The MIG-2/integrin interaction strengthens cell-matrix adhesion and modulates cell motility. J Biol Chem. 2007; 282(28): 20455-20466.
20. Moser M, Bauer M, Schmid S, et al. Kindlin-3 is required for beta2 integrin-mediated leukocyte adhesion to endothelial cells. Nat Med. 2009; 15(3): 300-305.
21. Harburger DS, Bouaouina M, Calderwood DA. Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J Biol Chem. 2009; 284(17): 11485-11497.
22. Larjava H, Plow EF, Wu C. Kindlins: Essential regulators of integrin signalling and cell-matrix adhesion. EMBO Rep. 2008; 9(12): 1203-1208.
23. Meves A, Stremmel C, Gottschalk K, et al. The Kindlin protein family: New members to the club of focal adhesion proteins. Trends Cell Biol. 2009; 19(10): 504-513.
24. Montanez E, Ussar S, Schifferer M, et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev. 2008; 22(10): 1325-1330.
25. Ye F, Petrich BG. Kindlin: Helper, co-activator, or booster of talin in integrin activatioñCurr Opin Hematol. 2011; 18(5): 356-360.
26. Cabodi S, del Pilar Camacho-Leal M, Di Stefano P, et al. Integrin signalling adaptors: Not only figurants in the cancer story. Nat Rev Cancer. 2010; 10(12): 858-870.
27. Papachristou DJ, Gkretsi V, Tu Y, et al. Increased cytoplasmic level of migfilin is associated with higher grades of human leiomyosarcoma. Histopathology. 2007; 51(4): 499-508.
28. Gozgit JM, Pentecost BT, Marconi SA, et al. Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. Mol Cancer Res. 2006; 4(12): 905-913.
29. Ma YQ, Qin J, Wu C, et al. Kindlin-2 (Mig-2): A co-activator of beta3 integrins. J Cell Biol. 2008; 181(3): 439-446.
30. Gong X, An Z, Wang Y, et al. Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death. Cancer Lett. 2010; 299(1): 54-62.
31. Ohuchida K, Mizumoto K, Murakami M, et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 2004; 64(9): 3215-3222.
32. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14(5): 518-527.
33. Navab R, Strumpf D, Bandarchi B, et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2011; 108(17): 7160-7165.
34. Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A. 2010; 107(5): 2177-2182.
35. Sung CO, Lee KW, Han S, et al. Twist1 is up-regulated in gastric cancer-associated fibroblasts with poor clinical outcomes. Am J Pathol. 2011; 179(4): 1827-1838.
36. Fujita H, Ohuchida K, Mizumoto K, et al. Alpha-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas. 2010; 39(8): 1254-1262.
37. Ohlund D, Lundin C, Ardnor B, et al. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer. 2009; 101(1): 91-97.
38. Kanno A, Satoh K, Masamune A, et al. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer. 2008; 122(12): 2707-2718.
39. Ikenaga N, Ohuchida K, Mizumoto K, et al. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology. 2010; 139(3): 1041-1051, 1051 e1041Ye1048.
40. Mackinnon AC, Qadota H, Norman KR, et al. C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes. Curr Biol. 2002; 12(10): 787-797.
41. Rogalski TM, Mullen GP, Gilbert MM, et al. The UNC-112 gene in Caenorhabditis elegans encodes a novel component of cell-matrix adhesion structures required for integrin localization in the muscle cell membrane. J Cell Biol. 2000; 150(1): 253-264.
42. He Y, Esser P, Schacht V, et al. Role of kindlin-2 in fibroblast functions: Implications for wound healing. J Invest Dermatol. 2011; 131(1): 245-256.
43. Dowling JJ, Vreede AP, Kim S, et al. Kindlin-2 is required for myocyte elongation and is essential for myogenesis. BMC Cell Biol. 2008; 9: 36.
44. Jung GY, Park YJ, Han JS. Mediation of Rac1 activation by kindlin-2: An essential function in osteoblast adhesion, spreading, and proliferation. J Cell Biochem. 2011; 112(9): 2541-2548.
45. Qu H, Tu Y, Shi X, et al. Kindlin-2 regulates podocyte adhesion and fibronectin matrix deposition through interactions with phosphoinositides and integrins. J Cell Sci. 2011; 124(Pt 6): 879-891.
46. Tu Y, Wu S, Shi X, et al. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell. 2003; 113(1): 37-47.
47. Shi X, Wu C. A suppressive role of mitogen inducible gene-2 in mesenchymal cancer cell invasion. Mol Cancer Res. 2008; 6(5): 715-724.
48. An Z, Dobra K, Lock JG, et al. Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration. Int J Cancer. 2010; 127(9): 1999-2008.
49. Shen Z, Ye Y, Dong L, et al. Kindlin-2: A novel adhesion protein related to tumor invasion, lymph node metastasis, and patient outcome in gastric cancer. Am J Surg. 2012; 203(2): 222-229.
50. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg. 2003; 237(1): 74-85.
51. Sahin TT, Fujii T, Kanda M, et al. Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas. Pancreas. 2011; 40(7): 1029-1033.
52. Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible? Ann Surg. 2008; 247(3): 456-462.
53. White RR, Xie HB, Gottfried MR, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005; 12(3): 214-221.
54. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol. 2001; 8(2): 123-132.